Results 81 to 90 of about 52,949 (209)

Aumolertinib Versus Osimertinib as First‐Line Treatment for EGFR‐Mutant Non‐Small Cell Lung Cancer: A Retrospective Real‐World Multicenter Study

International Journal of Cancer, Volume 159, Issue 10, Page 2575-2584, 15 November 2026.
As third‐generation EGFR‐tyrosine kinase inhibitors, both aumolertinib and osimertinib demonstrate clinical efficacy for non‐small cell lung adenocarcinoma, especially in patients with brain metastases. Currently, head‐to‐head studies comparing these two agents in real‐world settings are scarce.
Jinxia Wang, Ping Qi, Jinhua Li, Na Wang, Caihong Fu, Lixin Liu, Shuping Li, Xiao Li, Xiaoming Hou, Hui Qiao   +9 more
wiley   +1 more source

Clinical Experience with Gefitinib in Indian Patients [PDF]

, 2008
IntroductionTreatment options are limited in patients with advanced or refractory non-small cell lung cancer and lead to suboptimal outcome and/or benefit. The epidermal growth factor tyrosine kinase inhibitor gefitinib (IRESSA) has been approved in many
Parikh, Purvish, Ramesh Jagannathan, Dinesh Chandra Doval, Bhattacharyya, Gouri Shankar, Hargreaves, Laura, Advani, Suresh, Ranade, Anantbhushan, Doval, Dinesh Chandra, Chang, Alex Yuang-Chi, Chacko, Raju Titus, Jagannathan, Ramesh, Shyam Aggarwal, Digumarti, Raghunadharao, Purvish Parikh, Gouri Shankar Bhattacharyya, Babu, Govind, Aggarwal, Shyam, Suresh Advani, Govind Babu, Raju Titus Chacko, Laura Hargreaves, Nick Thatcher, Thatcher, Nick, Raghunadharao Digumarti, Nag, Shona, Alex Yuang-Chi Chang, Anantbhushan Ranade, Shona Nag   +27 more
core   +1 more source

Screening and Identification of MicroRNAs Related to Acquired Gefitinib-resistance 
in Lung Adenocarcinoma Cell Lines

Chinese Journal of Lung Cancer, 2011
Background and objective Acquired gefitinib-resistance was closely related to inefficiency of EGFR-TKI treatment in lung adenocarcinoma. However, it was not clear that how microRNAs influenced the acquired gefitinib-resistance in lung adenocarcinoma. The
Xuebo QIN, Bin LIU, Yang LI, Jiacong YOU, Qinghua ZHOU   +4 more
doaj   +1 more source

Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature

BMC Cancer, 2010
Background Gefitinib is one of the small molecule inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR TKIs). Clinical trials have demonstrated it is effective for treatment of a subset of patients with advanced non-small cell lung cancer
Liao Xin-Biao, Sun Xiao-Li, Wang Yi-Xiang J, Yang Jing-Song, Yan Sen-Xiang, Yan Dan-Fang, Liu Jun-Qing   +6 more
doaj   +1 more source

Surgical Removal of Residual Tumor Masses in Patients Undergoing Targeted Therapy for EGFR‐Mutated Locally Advanced or Metastatic Lung Cancer

International Journal of Cancer, Volume 159, Issue 9, Page 2244-2261, 1 November 2026.
Non‐small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations often exhibit significant tumor reduction following tyrosine kinase inhibitor (TKI) therapy. Residual tumors frequently remain, however, leading to drug resistance and disease progression.
Fedor Moiseenko, Daniil Stroyakovskiy, Evgeniy Levchenko, Mikhail Fedyanin, Albina Gabina, Ani Oganesian, Sergey Belukhin, Maria Stepanova, Ekaterina Stepanova, Elizaveta Artemyeva, Alexander Myslik, Nikita Volkov, Alexei Bogdanov, Tatiana Shuginova, Kirill Kryukov, Valeria Kheinshtein, Arif Allakhverdiev, Ivan Zaberegniy, Yana Akhmadiyarova, Mikhail Popov, Anastasiya Danilova, Dmitriy Sehniaidze, Nikita Savelov, Nikita Levchenko, Evgeniy Slugin, Olga Lopushanskaya, Ekaterina Kuligina, Svetlana Aleksakhina, Aglaya Iyevleva, Alexandr Ivantsov, Vladimir Moiseyenko, Evgeny Imyanitov   +31 more
wiley   +1 more source

Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy

, 2013
Yasoo Sugiura,1 Etsuo Nemoto,1 Osamu Kawai,2 Yasuyuki Ohkubo,2 Hisae Fusegawa,2 Shizuka Kaseda1 1Department of Pulmonary and Thoracic Surgery, 2Department of Respiratory Medicine, Kanagawa National Hospital, Hadano, Japan Background: Gefitinib is known ...
Ohkubo Y, Fusegawa H, Sugiura Y, Kaseda S, Nemoto E, Kawai O   +5 more
core  

A Randomized Clinical Study of Gefitinib and Pemetrexed as Second Line Therapy 
for Advanced Non-squamous Non-small Cell Lung Cancer

Chinese Journal of Lung Cancer, 2013
Background and objective Gefitinib and Pemetrexed are drugs used as second-line therapy for advanced non-small cell lung cancer (NSCLC), although studies comparing the two drugs are limited.
Hongyu DAI, Ling XU, Chunwei XIA, Wenping CHEN   +3 more
doaj   +1 more source

Serial ctDNA Analysis for Monitoring Molecular Response and Acquired Resistance in Metastatic NSCLC and HR+/HER2‐Negative Breast Cancer: A Real‐World Study

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Circulating tumor DNA (ctDNA) is a promising biomarker for disease monitoring, yet evidence of its clinical utility in routine care remains limited. We evaluated the utility of serial ctDNA monitoring using digital PCR (ddPCR) for detecting acquired resistance (AR) and monitoring response in metastatic non‐small cell lung cancer (NSCLC) and ...
Franciele Hinterholz Knebel, Maurício Fernando Silva Almeida Ribeiro, Rudinei Diogo Marques Linck, Isabela Flauzino Ferreira, Cibele Masotti, Rodrigo Saddi, Karina Perez Sacardo, Felipe Sales Nogueira Amorim Canedo, Leandro Jonata Carvalho Oliveira, Daniele Coelho Duarte, Paula Fontes Asprino, Ernande Xavier dos Santos, Elisângela Monteiro Coser, Dimitrios Kleftogiannis, Louise J. Barber, Marco Gerlinger, João Victor Machado Alessi, Andrea Kazumi Shimada, Fernando Costa Santini, Ciro Eduardo de Souza, Olavo Feher, Gilberto de Castro Junior, Frederico Perego Costa, Max Senna Mano, Artur Katz, Anamaria Aranha Camargo, Fabiana Bettoni   +26 more
wiley   +1 more source

M2 macrophages reduce the effect of gefitinib by activating AKT/mTOR in gefitinib‐resistant cell lines HCC827/GR

Thoracic Cancer, 2020
Background The biological behavior of cells change after they develop drug resistance, and the degree of resistance will be affected by the tumor microenvironment.
Fengqi Xiao, Ni Liu, Xinchun Ma, Jing Qin, Yanguo Liu, Xiuwen Wang   +5 more
doaj   +1 more source

Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo.

, 2008
The effects of the epidermal growth factor receptor (EGFR) inhibitor gefitinib on cell growth and signaling were evaluated in three medulloblastoma (MB) cell lines (D283, D341, Daoy), one supratentorial primitive neuroectodermal tumor cell line (PFSK ...
T. Servidei, Riccardo Riccardi, C. Ferlini, G. Cusano, Cristiano Ferlini, Gian Franco Zannoni, Riccardi, Anna Shirley, Ferlini, Cristiano, A. Riccardi, GIANGASPERO, FELICE, R. Riccardi, Servidei, Tiziana, Anna Riccardi, Felice Giangaspero, Meco, Daniela, D. Meco, Tiziana Servidei, Gabriella Cusano, Zannoni, Gian Franco, G. F. Zannoni, Riccardi, Riccardo, Daniela Meco   +21 more
core   +1 more source